for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Inovio Pharmaceuticals Reports Third Quarter Results

Nov 12 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.25.Q3 REVENUE $867,000 VERSUS $2.0 MILLION.Q3 REVENUE ESTIMATE $3.9 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.INOVIO PHARMACEUTICALS - AS OF SEPT 30, 2019, CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $93.8 MILLION VERSUS $81.2 MILLION AS OF DEC 31, 2018.

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (Gbm) Study With Ino-5401 In Combination With Pd-1 Inhibitor Libtayo (Cemiplimab)

Nov 5 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO DEMONSTRATES 80% 6-MONTH PROGRESSION-FREE SURVIVAL IN PHASE 2 GLIOBLASTOMA MULTIFORME (GBM) STUDY WITH INO-5401 IN COMBINATION WITH PD-1 INHIBITOR LIBTAYO® (CEMIPLIMAB).INOVIO PHARMACEUTICALS - ANNOUNCED POSITIVE INTERIM RESULTS FROM CO'S PHASE 2 STUDY OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.INOVIO PHARMACEUTICALS - IMMUNOTHERAPY COMBINATION WITH A PD-1 CHECKPOINT INHIBITOR EXHIBITED SUPPORTIVE SAFETY, TOLERABILITY, IMMUNOGENICITY DATA.

Inovio Pharmaceuticals Reports Q2 Loss Per Share $0.30

Aug 8 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.30.Q2 REVENUE $136,000.Q2 REVENUE ESTIMATE $5.7 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.

Inovio Pharma Expects To Incur A Personnel-Related Restructuring Charge Of About $2.3 Mln To Be Incurred Primarily In Q3 Of 2019

July 16 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS INC - EXPECTS TO INCUR A PERSONNEL-RELATED RESTRUCTURING CHARGE OF ABOUT $2.3 MILLION TO BE INCURRED PRIMARILY IN Q3 OF 2019.

Inovio Pharmaceuticals Says Has Cut Selected Early-Stage R&D Programs

July 16 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS INC - HAS CUT SELECTED EARLY-STAGE RESEARCH AND DEVELOPMENT PROGRAMS.INOVIO PHARMACEUTICALS INC - DISCONTINUED FURTHER DEVELOPMENT OF ITS PHASE 1/2 STUDY IN ADVANCED BLADDER CANCER.INOVIO PHARMACEUTICALS INC - REDUCING ITS WORKFORCE BY 28%..INOVIO PHARMACEUTICALS - "SHARPENED ITS CORPORATE STRATEGY TO FOCUS ON COMMERCIAL DEVELOPMENT OF ITS LATE-STAGE HPV ASSETS".INOVIO PHARMACEUTICALS INC - REALIGNMENT ENABLES INOVIO TO FOCUS ON COMMERCIALIZING LEAD ASSET VGX-3100.INOVIO PHARMACEUTICALS INC - REALIGNMENT ENABLES INOVIO TO FOCUS ON RE-DEPLOYING RESOURCES TO RAPIDLY ADVANCE INO-3107.INOVIO PHARMA - REALIGNMENT HELPS CO TO FOCUS ON PARTNERSHIP WITH ASTRAZENECA TO ADVANCE MEDI0457 IN WITH CHECKPOINT INHIBITOR IN HPV-RELATED CANCERS.INOVIO PHARMACEUTICALS - CONTINUES TO EXPECT INTERIM PROGRESSION-FREE SURVIVAL & SAFETY DATA FOR GBM BEFORE YEAR-END 2019, OVERALL SURVIVAL DATA IN 2020.

Qiagen NV Says Liquid Biopsy-Based Precision Medicine Test To Guide Patient Selection For Inovio's Vgx-3100

May 16 (Reuters) - Qiagen NV <QIA.DE>::QIAGEN AND INOVIO COLLABORATE TO DEVELOP COMPANION DIAGNOSTIC FOR NOVEL IMMUNOTHERAPY TARGETING PRECANCEROUS CERVICAL LESIONS.QIAGEN NV - LIQUID BIOPSY-BASED PRECISION MEDICINE TEST TO GUIDE PATIENT SELECTION FOR INOVIO'S VGX-3100.QIAGEN NV - INOVIO NOW AIMS TO MAKE REGULATORY SUBMISSIONS FOR VGX-3100 IN 2021.

Inovio Presents Cancer Killing Data Of Its Transformative Dna-Encoded Bi-Specific T Cell Engagers (Dbites) At Aacr

April 2 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PRESENTS CANCER KILLING DATA OF ITS TRANSFORMATIVE DNA-ENCODED BI-SPECIFIC T CELL ENGAGERS (DBITES) AT AACR.INOVIO PHARMACEUTICALS INC - DATA DEMONSTRATES TUMOR-CLEARING ABILITY OF INOVIO'S DBITE TECHNOLOGY IN PRECLINICAL CANCER MODEL.

Inovio Pharmaceuticals Posts Q4 Loss Per Share of $0.34

March 12 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS REPORTS 2018 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.34.QTRLY TOTAL REVENUE WAS $2.5 MILLION VERSUS $8.8 MILLION.

Inovio Pharma Appoints Jacqueline Shea As Chief Operating Officer

March 12 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO APPOINTS CHIEF OPERATING OFFICER; ANNOUNCES STRATEGIC MANAGEMENT CHANGES.APPOINTMENT OF JACQUELINE E. SHEA, PHD, AS INOVIO'S CHIEF OPERATING OFFICER (COO) AND EXECUTIVE VICE PRESIDENT.SHEA REPLACES DR. NIRANJAN Y. SARDESAI WHO NOW SERVES AS CHIEF EXECUTIVE OFFICER OF GENEOS THERAPEUTICS.MARK BAGARAZZI, FORMERLY CHIEF MEDICAL OFFICER, HAS LEFT COMPANY.

Inovio Pharma Prices $65 Mln Convertible Senior Notes Offering

Feb 14 (Reuters) - Inovio Pharmaceuticals Inc <INO.O>::INOVIO PHARMACEUTICALS PRICES $65.0 MILLION CONVERTIBLE SENIOR NOTES OFFERING.INOVIO PHARMACEUTICALS INC - PRICING OF ITS OFFERING OF $65.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6.50% CONVERTIBLE SENIOR NOTES DUE 2024.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up